November 2013 Editor's Picks: Products from Pall and I Holland - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

November 2013 Editor's Picks: Products from Pall and I Holland
Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Equipment and Processing Report

Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Pall
A single-use system provides flexible automation for biopharmaceutical manufacturing.

The Allegro MVP system from Pall is a fully automated platform that can be used across a range of upstream and downstream bioprocessing activities. A manifold selection tool facilitates selection of sensors, connectors, tubing type, filters, and prefilters needed for each application. Intuitive, easy-to-read labels on the manifold sets ease installation. The fully automated MVP system provides reliable control of process conditions and monitoring of all process variables, and the use of automated valves in the system allows more complex process steps to be simplified into an automated sequence. Automation enables precise and consistent operation and minimizes operator contact.

I Holland
Tablet-tooling coating improves punch and die performance

PharmaCote CX and CX+ (chromium nitride extra) tablet-tooling coatings from I Holland improve surface hardness, wear and corrosion resistance, and antisticking properties of punches and dies. The coating creates a smooth finish to help prevent tablet sticking, and multiple layers prolong tooling life. The new coatings offer up to 13 times more corrosion resistance than PharmaCote HC (hard chromium) and up to two times the life of PharmaCote CN (chromium nitride). The coating is also easy to clean and maintain using an ultrasonic bath and light, automated polishing.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Equipment and Processing Report,
Click here